1. Home
  2. MAIA vs IPWR Comparison

MAIA vs IPWR Comparison

Compare MAIA & IPWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MAIA
  • IPWR
  • Stock Information
  • Founded
  • MAIA 2018
  • IPWR 2007
  • Country
  • MAIA United States
  • IPWR United States
  • Employees
  • MAIA N/A
  • IPWR N/A
  • Industry
  • MAIA Biotechnology: Pharmaceutical Preparations
  • IPWR Industrial Machinery/Components
  • Sector
  • MAIA Health Care
  • IPWR Industrials
  • Exchange
  • MAIA Nasdaq
  • IPWR Nasdaq
  • Market Cap
  • MAIA 46.7M
  • IPWR 42.1M
  • IPO Year
  • MAIA 2022
  • IPWR 2013
  • Fundamental
  • Price
  • MAIA $1.73
  • IPWR $4.33
  • Analyst Decision
  • MAIA
  • IPWR Hold
  • Analyst Count
  • MAIA 0
  • IPWR 1
  • Target Price
  • MAIA N/A
  • IPWR N/A
  • AVG Volume (30 Days)
  • MAIA 417.6K
  • IPWR 49.2K
  • Earning Date
  • MAIA 08-08-2025
  • IPWR 08-13-2025
  • Dividend Yield
  • MAIA N/A
  • IPWR N/A
  • EPS Growth
  • MAIA N/A
  • IPWR N/A
  • EPS
  • MAIA N/A
  • IPWR N/A
  • Revenue
  • MAIA N/A
  • IPWR $19,296.00
  • Revenue This Year
  • MAIA N/A
  • IPWR N/A
  • Revenue Next Year
  • MAIA N/A
  • IPWR $5,900.00
  • P/E Ratio
  • MAIA N/A
  • IPWR N/A
  • Revenue Growth
  • MAIA N/A
  • IPWR N/A
  • 52 Week Low
  • MAIA $1.40
  • IPWR $3.77
  • 52 Week High
  • MAIA $4.24
  • IPWR $9.69
  • Technical
  • Relative Strength Index (RSI)
  • MAIA 41.47
  • IPWR 34.94
  • Support Level
  • MAIA $1.66
  • IPWR $3.81
  • Resistance Level
  • MAIA $1.95
  • IPWR $4.66
  • Average True Range (ATR)
  • MAIA 0.11
  • IPWR 0.30
  • MACD
  • MAIA -0.01
  • IPWR -0.08
  • Stochastic Oscillator
  • MAIA 7.82
  • IPWR 14.29

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.

About IPWR Ideal Power Inc.

Ideal Power Inc is pioneering the development of its broadly patented bidirectional power switches, creating efficient and ecofriendly energy control solutions for electric vehicles, electric vehicle charging, renewable energy, energy storage, UPS / data center, solid-state circuit breaker and other industrial and military applications. The company is focused on its patented Bidirectional, Bipolar Junction Transistor (B-TRAN) semiconductor technology. B-TRAN is a double-sided bidirectional AC switchable to deliver substantial performance improvements over conventional power semiconductors. The primary raw material used in the fabrication of B-TRAN devices is silicon wafers.

Share on Social Networks: